SIGNAL // COLOPHON
About TB-500 Chemical
What this project is, what it is not, and how it reads the literature.
What this project is
TB-500 Chemical is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 and its parent protein, thymosin beta-4. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site exists because the TB-500 record has a specific signal-integrity problem, and most of what is written about it online does not handle that problem honestly. The commercial heptapeptide (Ac-LKKTETQ, ~889 Da) is constantly conflated with full-length thymosin beta-4 (~4963 Da), whose data the marketing borrows. Our editorial job is to separate those two channels — to log which molecule each finding belongs to — and to cite every quantitative claim to its source.
What the name means
The "Chemical" in TB-500 Chemical is editorial framing, not a service claim. It marks the register we read the compound in: analytical characterization, structural definition, and the anti-doping detection literature — the lens in which TB-500 is best documented today. It does not mean the site supplies a chemical, tests one, or offers any product. There is no laboratory behind the name and nothing here is dispensed.
We do not have doctors, pharmacists, or a clinical team, and we do not offer treatment, consultation, or prescription services. Where this site describes the lawful compounding-access framework, it does so as general information about the regulatory landscape, drawn from a single audited FDA reference, and not as medical or legal advice.
How we handle evidence
Every quantitative statement on this site — a dose, a percentage, a half-life, an effect size — maps to a numbered citation in the reference register. When the literature is precise, we are precise; the embolic-stroke study's non-monotonic dose-response is reported with its exact milligram-per-kilogram values [4]. When the literature is silent, we say so; there are no completed controlled clinical trials of the TB-500 fragment for any indication [5].
We do not recommend doses for humans, we do not name vendors, and we do not link to other sites in our network. We describe what was administered, to which species, by which route, and we leave the reader to consult qualified professionals for anything beyond reading.